<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

MM.1R

Description

MM.1R (Multiple Myeloma CDX Model) 

The MM.1R multiple myeloma line was derived from a patient with plasma cell leukemia. It is resistant to glucocorticoids, making it useful in resistance mechanism studies. MM.1R retains features of malignant plasma cells, including immunoglobulin secretion. Its reproducibility supports hematology drug development pipelines. 

Key Features: 

  • Derived from plasma cell leukemia. 
  • Glucocorticoid-resistant line. 
  • Produces immunoglobulin light chains. 
  • Tumorigenic in xenograft systems. 

Applications: 
MM.1R is used in multiple myeloma resistance studies. It supports evaluation of therapies targeting glucocorticoid-resistant disease. Researchers use it to identify biomarkers and novel therapeutic strategies. Its biology makes it critical in advanced hematology research.

Details
Lymphoid
Multiple Myeloma
Human
Female
NOG
Lumin Data
Expression Data
Growth Curve